Cradle platform use expands across argenx antibody discovery programs

On November 17, 2026, Cradle announced that argenx is expanding use of Cradle’s AI-driven protein engineering platform to more scientists and antibody discovery programs, following successful initial work.

The platform has helped argenx optimize existing antibody leads and generate new candidates, with designs aimed at improving properties such as target affinity and selectivity.

In iterative design–test–learn cycles, argenx scientists explored sequence options beyond their starting candidates and conducted design work independently, enabling them to test a broader range of ideas and move promising designs forward faster.

argenx’s Head of Discovery, Bas Van Der Woning, said the company plans to extend platform access across discovery teams and apply it to more programs. The announcement frames the work as supporting argenx’s effort to turn immunology discoveries into antibody-based medicines.

The announcement did not identify specific antibody candidates, disease targets, clinical results, or timelines.

Sources:

Cradle's Antibody Discovery Platform for Autoimmune Diseases Supports ...

Cradle's Antibody Discovery Platform for Autoimmune Diseases Supports Scientific Mission of argenx

Rescuing a stalled IgG campaign: 10 candidates meeting ...

Drug discovery leader Marcus Schindler joins Cradle’s ...

How does AI change the first round of antibody optimization?

Cradle raises $24M Series A and signs partnerships with ...

Cradle raises $73M Series B to Put AI-Powered Protein Engineering in ...

We've raised $5.5M to design protein-machines and cell ...

Blog

UCB advances its digital antibody engineering program with new Cradle ...

Hansa Biopharma Partners with Cradle to Advance AI ...

Optimizing across the entire batch is one secret to better ...

Lundbeck partners with Cradle to discover and optimize ...

winning the Adaptyv Bio protein design competition

Four things protein engineers taught us at our first user meeting | Cradle